Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

  • US 9,186,346 B2
  • Filed: 02/04/2014
  • Issued: 11/17/2015
  • Est. Priority Date: 02/04/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin which is at the amount of about 50% of the normal dose of rosuvastatin.

View all claims

    Thank you for your feedback